Biomedical Data
Server Details
Biomedical data: compounds, drug info, and molecular targets
- Status
- Healthy
- Last Tested
- Transport
- Streamable HTTP
- URL
Glama MCP Gateway
Connect through Glama MCP Gateway for full control over tool access and complete visibility into every call.
Full call logging
Every tool call is logged with complete inputs and outputs, so you can debug issues and audit what your agents are doing.
Tool access control
Enable or disable individual tools per connector, so you decide what your agents can and cannot do.
Managed credentials
Glama handles OAuth flows, token storage, and automatic rotation, so credentials never expire on your clients.
Usage analytics
See which tools your agents call, how often, and when, so you can understand usage patterns and catch anomalies.
Tool Definition Quality
Average 3.3/5 across 3 of 3 tools scored.
Each tool targets a distinct data source and aspect: PubChem for chemical compound data, OpenFDA for regulatory and safety info, and ChEMBL for target and bioactivity data. There is no overlap in their purposes, making selection unambiguous.
All tools follow a consistent get_<object>_<data_type> pattern: get_compound_data, get_drug_info, get_drug_targets. The verb is always 'get' and the uses snake_case throughout, creating a predictable and uniform naming scheme.
With only 3 tools, the server is compact but covers three major drug-related databases. While a few more tools might round out the domain, the current count is reasonable and each tool earns its place.
The server covers chemical data, regulatory/safety information, and target/bioactivity data, providing a solid core for drug information retrieval. It lacks some common operations like search or batch retrieval, but for the stated purpose of getting specific data, the coverage is strong.
Available Tools
3 toolsget_compound_dataAInspect
Get drug/compound data from PubChem (NIH). Returns CID, IUPAC name, molecular formula, molecular weight, canonical SMILES, InChI, description, and synonyms.
| Name | Required | Description | Default |
|---|---|---|---|
| cid | No | PubChem CID number (alternative to name) | |
| name | No | Drug or compound name (e.g. aspirin, caffeine, ibuprofen) | aspirin |
Tool Definition Quality
Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?
No annotations are provided, so the description carries the full burden. It states the data source (PubChem) and the returned fields, but gives no behavioral context such as read-only nature, authentication requirements, rate limits, error conditions, or behavior on invalid input. It lacks caveats that would help the agent understand execution context.
Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.
Is the description appropriately sized, front-loaded, and free of redundancy?
The description is a single sentence that front-loads the action and resource, then lists the return fields in a compact, scannable manner. Every element is informative with no wasted words.
Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.
Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?
For a tool with 2 simple optional parameters and no output schema, the description covers the key context: data source, return fields, and query inputs via schema. It lacks usage guidance vs. siblings, but otherwise provides sufficient information for invocation and interpretation of results.
Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.
Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?
Schema description coverage is 100%, with both 'cid' and 'name' clearly described in the schema. The description does not add further semantics beyond listing return fields, which indirectly indicates that the parameters are query inputs. Baseline 3 is appropriate since the schema handles parameter documentation.
Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.
Does the description clearly state what the tool does and how it differs from similar tools?
The description uses a specific verb 'Get' and identifies the resource 'drug/compound data from PubChem (NIH)', then enumerates the return fields (CID, IUPAC name, etc.). This clearly states what the tool does and distinguishes it from sibling tools that target drug info or drug targets.
Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.
Does the description explain when to use this tool, when not to, or what alternatives exist?
The description implies usage when one needs compound data with the listed fields, but it does not explicitly state when to use this tool over get_drug_info or get_drug_targets, nor does it mention exclusions or alternatives. Guidance is only inferred from the return field list.
Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.
get_drug_infoBInspect
Get drug label, safety info, adverse events, or recall data from OpenFDA. Returns brand names, generic name, indications, warnings, dosage, interactions.
| Name | Required | Description | Default |
|---|---|---|---|
| name | No | Drug name (e.g. metformin, aspirin, lisinopril) | metformin |
| type | No | label (default), adverse_events, or recalls | label |
Tool Definition Quality
Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?
No annotations are provided, so the description must fully disclose behavior. It lists return fields, but the list appears specific to the default 'label' type and may not apply to adverse_events or recalls, creating an overgeneralization. It also does not mention error behavior, limitations, or that output varies by type.
Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.
Is the description appropriately sized, front-loaded, and free of redundancy?
Two sentences, front-loaded with the primary action and scope, followed by a concise list of return fields. No filler or unnecessary repetition.
Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.
Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?
The tool is simple with no required parameters and full schema coverage, and the description provides a purpose and return-field list, which is helpful given no output schema. However, it lacks clarity on how return fields vary by type and provides no usage guidance, so it is only minimally complete.
Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.
Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?
Schema description coverage is 100%, so the baseline is 3. The description adds the OpenFDA context and mentions data categories, but it does not add meaning beyond the schema's parameter descriptions for name and type.
Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.
Does the description clearly state what the tool does and how it differs from similar tools?
The description clearly states the tool gets drug label, safety info, adverse events, or recall data from OpenFDA, which is a specific resource and scope. It does not explicitly differentiate from sibling tools like get_compound_data or get_drug_targets, but the OpenFDA source and data categories provide reasonable clarity.
Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.
Does the description explain when to use this tool, when not to, or what alternatives exist?
No guidance is given on when to use this tool versus alternatives. It does not mention when to choose get_drug_info over get_compound_data or get_drug_targets, nor any exclusions or prerequisites.
Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.
get_drug_targetsBInspect
Get drug target and bioactivity data from ChEMBL (EMBL-EBI). Returns ChEMBL ID, max clinical phase, molecule type, molecular properties, and indication class.
| Name | Required | Description | Default |
|---|---|---|---|
| name | No | Drug or compound name (e.g. ibuprofen, atorvastatin) | ibuprofen |
| type | No | molecule (default) or activity | molecule |
| chembl_id | No | ChEMBL ID for activity lookup (e.g. CHEMBL521) |
Tool Definition Quality
Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?
The description discloses what data is returned (ChEMBL ID, clinical phase, etc.), which is useful. However, with no annotations, it does not disclose potential variations in behavior (e.g., how the 'type' parameter changes results), auth requirements, or whether results are singular or list-based. Moderate transparency for a read-only tool.
Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.
Is the description appropriately sized, front-loaded, and free of redundancy?
The description is one concise sentence, front-loads the main action, and includes the most relevant return information. No redundant or filler content.
Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.
Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?
Despite having no output schema and no annotations, the description does not explain how the optional parameters affect the request or what to expect when using 'type=activity'. It lists return fields but leaves important behavioral context (e.g., required vs optional inputs, mode differences) unaddressed. The tool is simple, but the description is incomplete for an agent to use it effectively in all valid configurations.
Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.
Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?
The schema already provides 100% description coverage for all three parameters, so the description adds little beyond the schema. It does not clarify parameter dependencies or how 'type' interacts with 'name'/'chembl_id', but the schema descriptions are adequate, warranting the baseline 3.
Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.
Does the description clearly state what the tool does and how it differs from similar tools?
The description clearly states it gets drug target and bioactivity data from ChEMBL, using a specific verb and resource. It lists return fields, but it does not explicitly distinguish itself from sibling tools like get_compound_data or get_drug_info, so it falls short of a 5.
Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.
Does the description explain when to use this tool, when not to, or what alternatives exist?
No guidance is provided on when to use this tool versus alternatives. It does not mention scenarios, exclusions, or sibling tool differentiators. The description is purely declarative with no usage context.
Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.
Claim this connector by publishing a /.well-known/glama.json file on your server's domain with the following structure:
{
"$schema": "https://glama.ai/mcp/schemas/connector.json",
"maintainers": [{ "email": "your-email@example.com" }]
}The email address must match the email associated with your Glama account. Once published, Glama will automatically detect and verify the file within a few minutes.
Control your server's listing on Glama, including description and metadata
Access analytics and receive server usage reports
Get monitoring and health status updates for your server
Feature your server to boost visibility and reach more users
For users:
Full audit trail – every tool call is logged with inputs and outputs for compliance and debugging
Granular tool control – enable or disable individual tools per connector to limit what your AI agents can do
Centralized credential management – store and rotate API keys and OAuth tokens in one place
Change alerts – get notified when a connector changes its schema, adds or removes tools, or updates tool definitions, so nothing breaks silently
For server owners:
Proven adoption – public usage metrics on your listing show real-world traction and build trust with prospective users
Tool-level analytics – see which tools are being used most, helping you prioritize development and documentation
Direct user feedback – users can report issues and suggest improvements through the listing, giving you a channel you would not have otherwise
The connector status is unhealthy when Glama is unable to successfully connect to the server. This can happen for several reasons:
The server is experiencing an outage
The URL of the server is wrong
Credentials required to access the server are missing or invalid
If you are the owner of this MCP connector and would like to make modifications to the listing, including providing test credentials for accessing the server, please contact support@glama.ai.
Discussions
No comments yet. Be the first to start the discussion!
Related MCP Servers
- AlicenseAqualityBmaintenancePre-clinical drug discovery intelligence MCP server providing 44 tools to query 800+ drug targets, 12K+ compounds, 46K+ papers, 18K+ clinical trials, and 16K+ patents.44Apache 2.0
- FlicenseAqualityBmaintenanceBiological and medical data search MCP server.432
- Alicense-qualityCmaintenanceNegative results intelligence for drug discovery: inactive compounds, failed selectivity panels, terminated clinical trials, failed CRISPR screens, antibody developability failures, and more — each result carrying full provenance (source database, DOI/PMID, license)1MIT
- Alicense-qualityCmaintenanceUnified MCP server providing AI-agent-ready access to AlphaFold, PubMed, ChEMBL, Ensembl, and 37+ scientific databases.MIT